Literature DB >> 10391528

Anticoagulant therapy in pregnancy.

F Robin1, F Lecuru, P Desfeux, V Boucaya, R Taurelle.   

Abstract

Anticoagulation during pregnancy should derive benefit from recent advances in anticoagulant therapy. Unfractionated heparin is at present the drug of choice for most of the indications of thromboprophylaxis as well as for acute venous thrombosis during pregnancy but it is likely that, in the near future, low molecular weight heparins will supercede this anticoagulant in many indications. One particular indication is mechanical heart valves that needs a high degree of anticoagulation. The anticoagulant of choice that carries the best efficacy-risk ratio in this situation seems to be oral anticoagulants. Pregnant women receiving anticoagulation should be considered as high-risk patients that should be managed in specialized centres. They are prone to bleeding complications that will mainly occur during delivery or in the postpartum period.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10391528     DOI: 10.1016/s0301-2115(99)00008-1

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  2 in total

1.  Coumarin embryopathy: long-term follow-up of two cases.

Authors:  Dieneke van Driel; Judit Wesseling; Tjalling W de Vries; Pieter J J Sauer
Journal:  Eur J Pediatr       Date:  2002-04       Impact factor: 3.183

2.  Adherence to a guideline for coumarins in pregnancy.

Authors:  Dieneke van Driel; Judit Wesseling; Kirsten ter Huurne; Lya M Geven-Boere; Frits R Rosendaal; Eveline van der Veer; Lolkje T W de Jong-van den Berg
Journal:  Pharm World Sci       Date:  2004-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.